Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $10.13, for a total transaction of $20,260.00. Following the completion of the transaction, the president now directly owns 2,827,018 shares in the company, valued at $28,637,692.34. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.09, for a total value of $24,180.00.
• On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.31, for a total value of $24,620.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.74, for a total value of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total transaction of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.

Gyre Therapeutics Stock Performance

GYRE opened at $9.71 on Friday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $19.00. The business has a fifty day simple moving average of $11.31 and a 200-day simple moving average of $12.20.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03). The firm had revenue of $27.87 million for the quarter, compared to analysts’ expectations of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new position in Gyre Therapeutics in the 4th quarter valued at approximately $1,225,000. FMR LLC acquired a new stake in shares of Gyre Therapeutics in the third quarter valued at $47,000. Charles Schwab Investment Management Inc. boosted its holdings in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the period. State Street Corp boosted its holdings in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares during the period. Finally, Barclays PLC grew its stake in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating on the stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.